You don’t often get excited about company mergers. That changed with today’s deal, especially if you have type 1 diabetes (T1D). The announcement Today, Vertex announced it is buying ViaCyte for $320 million in cash. This matters because both companies are developing stem cell therapies for people with T1D. Combining their efforts may speed up … Continue reading A big deal for type 1 diabetes
Viacyte
First patient in Type 1 diabetes clinical trial
There’s good news for a company and a therapeutic approach CIRM has supported for many years. ViaCyte's approach to T1D In September 2018, CRISPR Therapeutics and ViaCyte partnered. Together, they aim to develop gene‑edited, stem‑cell‑derived therapies for type 1 diabetes. Now, they may be one step closer. Last week, the companies jointly announced they had … Continue reading First patient in Type 1 diabetes clinical trial
Producing insulin for people who can’t
ViaCyte's implantable stem cell pouch One of CIRM's greatest strengths is supporting projects throughout the development process. Many promising ideas begin in the laboratory. Few advance to human clinical trials. CIRM helps bridge that gap by supporting research from early discovery through clinical testing. A recent announcement from ViaCyte highlights the value of that approach. … Continue reading Producing insulin for people who can’t
Stem Cell and Gene Editing Collaboration Advances Type 1 Diabetes Therapy
ViaCyte's implantable cell-based therapy for type 1 diabetes Turning a promising discovery into a patient therapy takes years of research and strong partnerships. That is exactly what two leading biotechnology companies have done. ViaCyte and CRISPR Therapeutics have combined stem cell science and gene-editing technology to develop a potential new treatment for type 1 diabetes … Continue reading Stem Cell and Gene Editing Collaboration Advances Type 1 Diabetes Therapy
Exploring New Stem Cell Therapies for Type 1 Diabetes
Type 1 diabetes (T1D) affects millions of people and requires constant attention. For patients and families, managing the disease can be physically and emotionally demanding. People with T1D must carefully monitor their blood sugar levels throughout the day. They must also balance meals, activity levels, and insulin doses to keep glucose within a healthy range. … Continue reading Exploring New Stem Cell Therapies for Type 1 Diabetes
Breakthrough for type 1 diabetes: scientist discovers how to grow insulin-producing cells
Matthias Hebrok, PhD, senior author of new study that transformed human stem cells into mature, insulin-producing cells. Photo courtesy of UCSF. Most people don’t think about their blood sugar before enjoying a meal, dessert, or bike ride. But for people with type 1 diabetes (T1D), every minute and every action revolves around the number on … Continue reading Breakthrough for type 1 diabetes: scientist discovers how to grow insulin-producing cells
CIRM-supported Type I Diabetes treatment enters clinical trials in Europe
ViaCyte, a company that CIRM has supported for many years, has announced international expansion of a clinical trial to test their therapeutic PEC-Direct product in patients with Type I Diabetes. The first European patient in Brussels was implanted with the PEC-Direct product candidate that, in animal models, is able to form functional beta cells. Patients … Continue reading CIRM-supported Type I Diabetes treatment enters clinical trials in Europe
How CIRM support helped a promising approach to type 1 diabetes get vital financial backing
The “Valley of Death” sounds like a scary place from “Lord of the Rings” or “Game of Thrones” that our heroes have to navigate to reach safety. The reality is not that different. It’s the space that young companies have to navigate from having a good idea to getting financial backing, so they can move … Continue reading How CIRM support helped a promising approach to type 1 diabetes get vital financial backing
New partnership to make CIRM supported treatment for type 1 diabetes even better
ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better
CIRM-Funded Research Makes Multiple Headlines this Week
When it rains it pours. This week, multiple CIRM-funded studies appeared in the news, highlighting the exciting progress our Agency is making towards funding innovative stem cell research and promoting the development of promising stem cell therapies for patients. Below are highlights. Fate Therapeutics Partners with UC San Diego to Develop Cancer Immunotherapy Last week, … Continue reading CIRM-Funded Research Makes Multiple Headlines this Week